Data from the ACTIVATION trial show that primary endpoints of death and rehospitalization at 1 year were similar between percutaneous coronary intervention (PCI) and no PCI in patients undergoing transcatheter aortic valve replacement (TAVR). However, the noninferiority margin was not met.